A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

The goal of this study is to build on the experience of the SAINT trial by evaluating the safety and efficacy of the addition of pazopanib to their published chemotherapy regimen.

开始日期2026-08-31

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT07076186

/ Recruiting临床2期IIT

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in Uterine Leiomyosarcoma

To find out if receiving standard chemotherapy (doxorubicin and trabectedin) can extend the cancer-free survival of patients with Stage 1b/2 uterine leiomyosarcoma who had surgery that fully removed the tumor.

开始日期2025-10-02

申办/合作机构

The University of Texas MD Anderson Cancer Center

KCT0010448

/ Not yet recruiting临床2期IIT

Randomized controlled trial evaluating the combination of chemotherapy and radiation therapy in gynecologic soft tissue sarcoma(Susbstudy 2 : Randomized comparison of doxorubicin/trabectedin versus doxorubicin/trabectedin plus radiation therapy in advanced or metastastic or unresectable leiomyosarcoma (uterine or soft tissue)

开始日期2025-04-30

申办/合作机构

Asan Medical Center

100 项与曲贝替定相关的临床结果

登录后查看更多信息

100 项与曲贝替定相关的转化医学

登录后查看更多信息

100 项与曲贝替定相关的专利（医药）

登录后查看更多信息

1,171

项与曲贝替定相关的文献（医药）

2026-05-01·Cancer pathogenesis and therapy

Exploring marine-derived compounds as potential anti-cancer agents: Mechanisms and therapeutic implications

Review

作者: Ekghara, Sumit Dilip ; Bandaru, Nagaraju ; Patil, Yash Pramod ; Patil, Kunal Sharad ; Bonthu, Mohan Gandhi

Marine-derived compounds have emerged as a promising frontier in cancer research due to their remarkable structural diversity and broad-spectrum bioactivities. The marine environment, encompassing diverse organisms (e.g., sponges, algae, tunicates, mollusks, and marine microbes), is a prolific source of novel bioactive molecules with potent anti-cancer properties. Key classes of these compounds include alkaloids, polysaccharides, peptides, terpenoids, and polyketides, which exert anti-tumor effects through diverse mechanisms, including the induction of apoptosis, inhibition of angiogenesis, modulation of immune responses, interference with cell cycle progression, and targeting of critical signaling pathways involved in tumorigenesis and metastasis. Notably, marine-derived drugs such as trabectedin, eribulin, and plitidepsin have received regulatory approval for the treatment of various malignancies, demonstrating the translational potential of these natural compounds. Ongoing clinical and preclinical investigations are exploring a wide range of marine metabolites for their cytotoxic, anti-proliferative, and chemosensitizing properties. Advances in marine biotechnology, including genome mining, synthetic biology, and fermentation technologies, have significantly facilitated the discovery, sustainable production, and structural optimization of marine natural products. However, challenges such as low yield, structural complexity, limited water solubility, and poor bioavailability hinder their broader clinical application. The integration of novel drug delivery systems, such as nanoparticles, liposomes, and conjugates, offers a viable solution to overcome these limitations and improve pharmacokinetic profiles. This review provides a comprehensive overview of the mechanisms of action, therapeutic applications, and clinical development of marine-derived anti-cancer compounds. It also emphasizes the need for deeper insights into their molecular targets and the potential for synergistic use with existing chemotherapeutic agents. Future directions should focus on exploring untapped marine biodiversity, developing eco-friendly harvesting strategies, and developing innovative delivery platforms to fully harness the therapeutic promise of the marine pharmacopeia in oncology.

2026-04-01·Gynecologic Oncology Reports

Acute myocardial infarction caused by coronary tumor embolism from uterine leiomyosarcoma: a case report

Article

作者: Koyanagi, Takahiro ; Fujiwara, Hiroyuki ; Shinohara, Miki ; Takahashi, Yoshifumi ; Tamura, Kohei ; Taneichi, Akiyo ; Shirasu, Yumi ; Takei, Yuji

Background:

Tumor embolism to the coronary arteries is an extremely rare cause of acute myocardial infarction (AMI). It has been reported in lung and breast cancers but not in uterine leiomyosarcoma. Herein, we present a case of AMI caused by a coronary tumor embolism from uterine leiomyosarcoma, which was successfully treated with aspiration thrombectomy.

Case presentation:

A 51-year-old woman with metastatic uterine leiomyosarcoma underwent surgical resection followed by adjuvant chemotherapy. During her second trabectedin cycle, she developed acute chest pain and dyspnea. Electrocardiography revealed anterior AMI. Emergency coronary angiography demonstrated complete occlusion of the left anterior descending and circumflex arteries. Thrombus aspiration completely restored coronary flow. Histopathological examination of the aspirated material confirmed leiomyosarcoma. Following aspiration, her symptoms subsided and she was discharged and prescribed cardioprotective medications. No recurrent cardiac events occurred.

Conclusion:

While most AMI events result from thrombotic occlusion and respond to anticoagulation, tumor emboli require mechanical intervention. Aspiration thrombectomy proved effective in this case. Clinicians should recognize that tumor embolism can induce AMI even in previously unreported cancer types, as pulmonary metastases may invade the pulmonary veins enabling tumor fragments to enter systemic circulation. Early recognition and intervention are critical for survival in these patients. Tumor embolism should be considered in the differential diagnosis of patients with cancer presenting with unexplained chest pain or dyspnea.

2026-04-01·ANNALS OF ONCOLOGY

Trabectedin–olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group

Article

作者: Buonadonna, A ; Sbaraglia, M ; Paioli, A ; Baldi, G G ; Vincenzi, B ; Merlini, A ; Berrino, E ; Tolomeo, F ; Righi, L ; Gurrieri, L ; Sanfilippo, R ; Stacchiotti, S ; Pignochino, Y ; Rabino, M ; Sangiolo, D ; Bellomo, S E ; Ferraresi, V ; Brunello, A ; Pantaleo, M A ; Dei Tos, A P ; De Pas, T M ; Badalamenti, G ; Grignani, G ; Aliberti, S ; D'Ambrosio, L ; Marchiò, C

BACKGROUND:

Advanced/metastatic soft tissue sarcomas (STSs) remain an unmet clinical need. We previously reported the feasibility and preliminary activity of trabectedin-olaparib combination in patients with advanced STS progressing after anthracycline-based regimens.

PATIENTS AND METHODS:

In this investigator-initiated, open-label, phase II randomized trial, adult patients with advanced STS progressing after one or more prior lines of therapy, including at least one anthracycline-based regimen, were randomly assigned 1 : 1 to trabectedin 1.1 mg/m² every 21 days (q21d) intravenous (i.v.) plus olaparib tablets 150 mg twice a day, or trabectedin 1.5 mg/m² q21d i.v. Randomization stratified patients by histology (L-sarcoma, i.e. leiomyosarcoma and liposarcoma versus non-L-sarcoma) and number of prior therapies (one versus two or more). The primary endpoint was progression-free survival (PFS) rate at 6 months (PFS6m) per RECIST1.1. Secondary endpoints included PFS, overall survival (OS), RECIST1.1 overall response rate (ORR), and safety. Exploratory endpoints encompassed biomarker/molecular analyses.

RESULTS:

Between 25 May 2020 and 2 November 2022, 130 patients were enrolled at 13 Italian Sarcoma Group centers (81 female; 67 L-sarcoma; 93 one prior line). With a median follow-up of 37.4 months, PFS6m and median PFS were 32% [95% confidence interval (CI) 22% to 46%] and 3.9 months (95% CI 2.7-5.2 months) with trabectedin-olaparib versus 28% (95% CI 19% to 42%) and 2.9 months (95% CI 2.2-3.6 months) with trabectedin [hazard ratio (HR) 0.722, 95% CI 0.501-1.041, P = 0.081]. Among 126 assessable patients, ORR was 12.7% (95% CI 6.1% to 22.7%) versus 7.9% (95% CI 3.0% to 16.7%), respectively (odds ratio 1.60, 95% CI 0.50-5.16, P = 0.43). In the uterine leiomyosarcoma subgroup, 12-month PFS was 42.9% with trabectedin-olaparib versus 0% with trabectedin. PARP1 expression significantly correlated with improved PFS with trabectedin-olaparib (PFS6m and median PFS were 41.5% and 4.3 months versus 27.8% and 2.5 months; HR 0.537, 95% CI 0.337-0.855, P = 0.009). Grade ≥3 hematological toxicities were significantly more frequent with trabectedin-olaparib.

CONCLUSIONS:

Although trabectedin-olaparib combination reached the prespecified threshold for statistical significance for PFS (P < 0.10), the benefit was marginal in the all-comers STS population. Nonetheless, patients affected by PARP1-expressing STS and uterine leiomyosarcoma derived substantial benefit from the combination, supporting further histology- and biomarker-driven investigation in these settings.

144

项与曲贝替定相关的新闻（医药）

2026-04-20

·PRNewswire

New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore

ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) [1],[2] SCLC is an aggressive form of lung cancer, accounting for 10-15% of all lung cancer diagnoses [3]-[6] Lung cancer is the leading cause of cancer death in Australia and among men in Singapore, and the second highest among Singaporean women [7]-[9] April 20, 2026 -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the approval of ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), as a new first-line maintenance treatment option for adult patients in Australia and Singapore, who have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer.[1],[2] This follows the recent decision by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to issue a positive opinion recommending the approval of ZEPZELCA in Europe.[10] In combination with atezolizumab, ZEPZELCA has been approved for use in Australia and Singapore as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) in adult patients whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.[1],[2] Both approvals for ZEPZELCA in ES-SCLC were obtained under Project Orbis — an initiative of the United States Food and Drug Administration's (US FDA's) Oncology Center of Excellence. These ZEPZELCA approvals represent the eighth time ST has successfully navigated the Project Orbis process since 2021. Lung cancer remains a significant health challenge in the region, with an estimated 15,000 diagnoses and 9,000 deaths from the disease each year in Australia.[7],[8] In Singapore, lung cancer is the third most common cancer, with 9,732 new cases diagnosed between 2019-2023.[11] Small cell lung cancer (SCLC) is a highly aggressive cancer that has often already spread to other organs when first diagnosed.[6] It accounts for approximately 10-15% of all lung cancer cases and has a low 5-year survival rate of under 7%.[6] Professor Nick Pavlakis, Medical Oncologist from Royal North Shore Hospital in Sydney, acknowledged the approval of the new combination therapy as an important step in helping to improve outcomes for patients with ES-SCLC. "Most patients with small cell lung cancer typically present with extensive-stage disease at diagnosis, meaning they are often faced with experiencing high rates of relapse or recurrence, limited treatment options and a poor prognosis," said Professor Pavlakis. "While outcomes for patients have improved over the past five years with the addition of immunotherapy to chemotherapy, there continues to be a significant clinical need to improve on first-line therapies used to treat extensive-stage small cell lung cancer to prolong disease control and enhance survival. Today's announcement is welcome news for the medical and patient community." ZEPZELCA is being made available in Australia, New Zealand, Singapore, Malaysia, Thailand and Vietnam by Specialised Therapeutics (ST), under exclusive license from European biopharmaceutical company PharmaMar, which has pioneered the development of marine-based oncology medicines. ST Chief Executive Officer, Mr Carlo Montagner, said the approval of ZEPZELCA for ES-SCLC in the first-line setting would provide clinicians and patients with an important new therapeutic option for this difficult to treat cancer. "We are delighted to have secured regulatory approvals for ZEPZELCA in combination with atezolizumab as a first-line maintenance therapy for adults diagnosed with ES-SCLC in Australia and Singapore," said Mr Montagner. "Despite the improved efficacy of first-line therapies for ES-SCLC that have been available since 2019, survival outcomes remain suboptimal, with an estimated 40% of patients experiencing a relapse and requiring second-line treatment. The availability of additional first-line treatment options will enable eligible patients and their clinicians to find the therapy that is right for them, can help to improve their quality of life and importantly, give them more time to spend with their families and loved ones." Chief Medical Officer for PharmaMar, Javier Jimenez, welcomed the regulatory approval for ZEPZELCA, saying: "We are very pleased that patients in Australia and Singapore can have access to this new therapy, as it marks an important milestone in the management of this disease, where a significant unmet medical need persists. Building on more than 40 years of commitment to research in diseases with limited treatment options, we will continue to collaborate with our partner in Australia to enable timely and equitable access to this new treatment." ZEPZELCA belongs to a class of medicines known as alkylating agents, which work by damaging the DNA of cancer cells, helping to slow or stop their growth.[12] The regulatory approvals for ES-SCLC in Australia and Singapore were based on results from the Phase 3 IMforte clinical trial. The study enrolled 660 treatment-naïve patients with ES-SCLC across 13 countries in the induction phase. Following this, 483 patients who responded to induction treatment were randomised to receive either ZEPZELCA with atezolizumab (LU-AT) or atezolizumab monotherapy (AT) as first-line maintenance therapy.[13] The trial results supported the use of LU-AT as a new first-line maintenance treatment option over AT alone in patients with this aggressive cancer, with improvements recorded in both median progression free survival (PFS; 5.4 months vs. 2.1 months) and median overall survival (OS; 13.2 months vs.10.6 months).[13] Significant variations in treatment-related adverse events (AEs) were noted in the two trial groups (83.5% in patients receiving LU-AT vs. 40% among patients receiving AT monotherapy).[13] Treatment with LU-AT was considered to be generally well tolerated, with no new or unexpected safety signals.[13] The most common adverse reactions (≥ 30%), including laboratory abnormalities, in patients who received ZEPZELCA with atezolizumab were decreased lymphocytes, decreased platelets, decreased haemoglobin, decreased leukocytes, decreased neutrophils, nausea, and fatigue/asthenia. ZEPZELCA® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumours are particularly dependent. Together with its effect on cancer cells, ZEPZELCA inhibits oncogenic transcription in tumour-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumour. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets. In Australia and Singapore, ZEPZELCA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) that has progressed on or after prior platinum-containing therapy.[1],[2] The IMforte clinical trial was a randomised, multicentre, open-label, Phase 3 trial of 660 treatment-naive patients with ES-SCLC conducted across 96 hospitals and medical centres in 13 countries, including Belgium, Germany, Greece, Hungary, Italy, Mexico, Poland, South Korea, Spain, Taiwan, Türkiye, the UK and the US. The trial evaluated the efficacy and safety of lurbinectedin (ZEPZELCA®) combined with atezolizumab (Tecentriq®) as first-line maintenance therapy (LU-AT), compared to treatment with atezolizumab alone (AT) for patients with ES-SCLC, following first-line induction therapy with atezolizumab, carboplatin and etoposide. Of the 660 enrolled patients, 483 were randomised to receive treatment with LU-AT (n=242) or AT monotherapy (n=241). The IMforte trial demonstrated that treatment with LU-AT as a first line regimen offers clinical advantages over AT alone in patients with ES-SCLC, with significant improvements to median progression-free survival (PFS; 5.4 months vs. 2.1 months) and median overall survival (13.2 months vs.10.6 months) observed. Treatment-related adverse events (AEs) occurred in 83.5% of patients who received LU-AT, compared with 40% in the AT arm. This variation was observed in patients who experienced a grade 3/4 AE (25.6% vs. 5.8%), a grade 5 AE (0.8% vs. 0.4%) and AEs that led to treatment discontinuation (6.2% vs. 3.3%). However, treatment with LU-AT was considered to be generally well tolerated, with no new or unexpected safety signals. The trial results suggest that LU-AT may serve as a novel first-line maintenance treatment option for patients with ES-SCLC. Founded in 2007, Specialised Therapeutics is an independent specialty pharmaceutical company, providing novel therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions across multiple therapeutic areas. The ST mission is to provide specialty therapies where there is an unmet need to communities that would otherwise not have ready access to such therapies. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation. PharmaMar has developed and now commercialises Yondelis® in Europe by itself, as well as ZEPZELCA® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). The content above comes from the network. if any infringement, please contact us to modify.

临床结果上市批准免疫疗法引进/卖出

2026-04-20

·道道之道

【本周医刊】2026年第16周医学期刊更新

2026年第16周（2026.04.12-2026.04.18）重要医学期刊论著更新如下： 1.综合期刊 LANCET 题目：Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial 翻译：瑞拉考瑞兰联合白蛋白结合型紫杉醇用于铂耐药卵巢癌患者的总生存期（ROSELLA）：一项Ⅲ期随机对照试验题目：Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study 翻译：帕博利珠单抗联合周疗紫杉醇治疗铂耐药复发性卵巢癌（ENGOT-ov65/KEYNOTE-B96）：一项多中心、随机、双盲Ⅲ期研究题目：Non-surgical casting versus surgical reduction for children with severely displaced distal radial fractures (the CRAFFT Study): a multicentre, randomised, controlled non-inferiority trial and economic evaluation 翻译：非手术石膏固定对比手术复位治疗儿童严重移位桡骨远端骨折（CRAFFT研究）：一项多中心、随机、对照非劣效性试验及卫生经济学评价 NEW ENGLAND JOURNAL OF MEDICINE 题目：Asundexian for Secondary Stroke Prevention 翻译：阿孙德西班用于卒中二级预防题目：Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease 翻译：泼尼松龙辅助治疗川崎病的随机试验题目：Selective Decontamination of the Digestive Tract during Ventilation in the ICU 翻译：ICU 机械通气期间消化道选择性去污染题目：Ianalumab plus Eltrombopag in Immune Thrombocytopenia 翻译：伊纳鲁单抗联合艾曲泊帕治疗免疫性血小板减少症 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 题目：A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder: A Randomized Clinical Trial 翻译：用于重度抑郁症个体化抗抑郁治疗的决策支持系统：一项随机临床试验题目：Restrictive vs Liberal Physical Restraint Strategies in Critically Ill Patients: The R2D2-ICU Randomized Clinical Trial 翻译：危重患者限制性与宽松性身体约束策略对比：R2D2-ICU随机临床试验题目：Hospital Adoption and Pricing for Oncology Biosimilars 翻译：肿瘤生物类似药在医院的应用普及与定价情况 NATURE MEDICINE 题目：Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial 翻译：曲贝替定联合低剂量伊立替康靶向尤因肉瘤EWS::FLI1 融合基因：一项Ⅰ/Ⅱ期临床试验题目：Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma 翻译：整合流行病学与分子数据阐明食管腺癌癌前病变与癌变状态的关联题目：Rapid expansion of genotype D1.1 A(H5N1) influenza viruses in wild birds across North America during the 2024 migratory season 翻译：2024 年迁徙季D1.1 亚型A (H5N1) 禽流感病毒在北美野生鸟类中快速扩散题目：An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration 翻译：脑脊液乙酰化 Tau-174 生物标志物可鉴别额颞叶变性患者的TDP-43 与tau 病理题目：Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1high-risk genotypes 翻译：基于APOL1高危基因型人群的蛋白质组风险评分用于早期预测肾病进展题目：Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1epileptic encephalopathy 翻译：反义寡核苷酸介导的基因敲低疗法治疗2 例重症KCNT1癫痫性脑病婴儿题目：Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial 翻译：玻璃体内光开关疗法治疗晚期视网膜色素变性：一项Ⅰ期开放标签试验题目：Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial 翻译：艾尔拉昔布联合化疗治疗转移性胰腺导管腺癌：一项Ⅱ期随机对照试验 BMJ-BRITISH MEDICAL JOURNAL 题目：Effectiveness of interventions to increase vaccine uptake 翻译：提升疫苗接种率干预措施的有效性题目：Prenatal exposure to buprenorphine or methadone and adverse neurodevelopmental outcomes 翻译：产前暴露于丁丙诺啡或美沙酮与不良神经发育结局 LANCET DIGITAL HEALTH 题目：Artificial intelligence-based pathological model for pan-cancer lymph node metastasis detection: a multicentre diagnostic study with retrospective and prospective validation 翻译：基于人工智能的泛癌淋巴结转移检测病理模型：一项含回顾性与前瞻性验证的多中心诊断研究题目：A predictive atlas of disease onset from retinal fundus photographs: a modelling study using data from population-based cohorts 翻译：基于眼底照片的疾病发病预测图谱：一项基于人群队列数据的建模研究题目：Identification of drug repurposing candidates for amyotrophic lateral sclerosis using electronic health records: a retrospective cohort study 翻译：利用电子健康记录筛选肌萎缩侧索硬化候选老药新用靶点：一项回顾性队列研究题目：A multiagent large language model-based system to simulate the liver transplant selection committee: a retrospective cohort study 翻译：基于多智能体大语言模型系统模拟肝移植遴选委员会决策：一项回顾性队列研究 NPJ DIGITAL MEDICINE 题目：Bias, representation, and clinical fidelity in AI-generated images for medical education: a systematic literature review 翻译：人工智能生成医学教育图像中的偏倚、代表性与临床真实性：一项系统文献综述题目：AI Augmented Confocal Laser Endomicroscopy for Rapid Intraoperative Diagnosis of Brain Tumors 翻译：AI 增强共聚焦激光内镜在脑肿瘤术中快速诊断中的应用题目：Development and prospective shadow evaluation of a domain-specific large language model for emergency neurological diagnosis 翻译：面向急诊神经科诊断的领域专用大语言模型构建与前瞻性模拟评估题目：Predictive models for the occurrence and lymph node metastasis of papillary thyroid carcinoma with regional risk heterogeneity 翻译：区域风险异质性背景下甲状腺乳头状癌发生及淋巴结转移预测模型题目：Patch-to-slide fusion deep learning model for histological diagnosis of early pregnancy loss including hydatidiform mole 翻译：用于葡萄胎等早期妊娠丢失组织学诊断的切片级融合深度学习模型题目：A scoping review of the characteristics, responsibilities, implementations and evaluations of digital navigators in healthcare 翻译：医疗领域数字导航员特征、职责、实施与评估范围综述题目：Development and validation of a novel blood-based biomarker for gastric cancer triage in chronic dyspepsia 翻译：用于慢性消化不良患者胃癌分流筛查的新型血液学生物标志物构建与验证题目：Differentiable centerline-aware framework for aneurysm neck delineation in volumetric angiography 翻译：基于可微分中心线感知框架的容积血管造影动脉瘤颈delineation 题目：Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis 翻译：人工智能辅助路径下糖尿病视网膜病变筛查后转诊依从性：系统回顾与荟萃分析题目：Predicting clinically significant prostate cancer with or without digital rectal exam and MRI data using ClarityDX Prostate models 翻译：基于 ClarityDX Prostate 模型联合/ 不联合直肠指检及MRI 数据预测临床显著性前列腺癌题目：Real-time AI-assisted quality control during nasopharyngolaryngoscopy: a randomized controlled trial 翻译：鼻咽喉镜检查中实时 AI 辅助质量控制：一项随机对照试验题目：Automated deep learning for real-time focal liver lesions detection in ultrasound videos a multicenter study 翻译：基于自动化深度学习的超声视频实时肝脏局灶性病变检测：多中心研究题目：The effects of multitype prompt engineering for large language models in hypertension treatment decisions 翻译：大语言模型多类型提示工程对高血压治疗决策的影响题目：Specialized foundation models for intelligent operating rooms 翻译：面向智能手术室的专用基础模型题目：An agentic AI system for automated pharmacogenomic recommendation generation 翻译：用于自动化药物基因组学推荐生成的自主AI 系统题目：Seven deadly sins in artificial intelligence for digital medicine 翻译：数字医学人工智能领域的“七宗罪” 题目：Evaluating real-world deployment of an HL7-CDA-aligned LLM for ICD-10-CM coding 翻译：基于 HL7-CDA 规范的大语言模型在ICD-10-CM 编码中真实世界应用评估题目：Large language model-augmented offline reinforcement learning framework for sepsis management in critical care 翻译：面向重症脓毒症管理的大语言模型增强离线强化学习框架题目：Mapping AI startup investment and innovation in healthcare using a five-tier AI systems complexity framework 翻译：基于五层 AI 系统复杂度框架的医疗AI 初创企业投资与创新图谱分析题目：PsychiatryBench: a multi-task benchmark for LLMs in psychiatry 翻译：PsychiatryBench：面向精神病学领域大语言模型的多任务基准测试集 2.肿瘤学 CA-A CANCER JOURNAL FOR CLINICIANS 题目：Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta‐analysis 翻译：用于癌症患者及其家属照护者缓解痛苦、焦虑与抑郁的非药物干预措施：一项系统评价与荟萃分析 ANNALS OF ONCOLOGY 题目：Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914) 翻译：WSG ADAPT-HR+/HER2- 及ADAPTcycle 研究（N=7914）：术前短期内分泌治疗后内分泌疗效应答的临床与分子生物标志物预测题目：DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers 翻译：DART 研究（NCI/SWOG S1609）：CTLA-4与PD-1 双重免疫检查点抑制治疗罕见癌种的最终完整结果题目：A Simple Plan: Chemotherapy-Sparing Approaches to Early Stage and Regional Seminoma and Non-Seminoma 翻译：简明方案：早期及区域性精原细胞瘤与非精原细胞瘤的免化疗治疗策略题目：Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 翻译：转移性结直肠癌：ESMO 诊断、治疗与随访临床实践指南 JOURNAL OF CLINICAL ONCOLOGY 题目：Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII) 翻译：超低剂量免疫治疗用于复发难治性实体瘤的疗效与安全性：Ⅲ期优效性随机试验（DELII）题目：Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study 翻译：帕博利珠单抗联合或不联合仑伐替尼作为复发或转移性头颈部鳞状细胞癌一线治疗：Ⅲ期LEAP-010 研究题目：VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer 翻译：Gedatolisib 联合氟维司群±帕博西尼治疗激素受体阳性/ HER2 阴性/ PIK3CA 野生型晚期乳腺癌的VIKTORIA-1 试验题目：Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial 翻译：纳武利尤单抗±伊匹木单抗治疗经治晚期神经内分泌癌：GCO-001 NIPINEC 随机Ⅱ期试验题目：Financial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screening 翻译：确诊前的经济困境：对癌症晚期就诊的影响及筛查的作用 LANCET ONCOLOGY（本周无更新） JOURNAL OF THORACIC ONCOLOGY（本周无更新） JAMA ONCOLOGY 题目：Survival of Patients Diagnosed With Cancer During the COVID-19 Pandemic 翻译：新冠疫情期间确诊癌症患者的生存情况题目：Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer 翻译：局限性放疗后复发前列腺癌：挽救性局部治疗vs 前列腺癌根治术题目：Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial 翻译：晚期乳腺癌中一线与二线使用 CDK4/6 抑制剂的总生存期比较：一项随机临床试验题目：First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial 翻译：替雷利珠单抗联合化疗一线治疗复发或转移性鼻咽癌：Ⅲ期RATIONALE-309 随机临床试验三年随访结果题目：Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial 翻译：CHOP 方案联合抗CD20 治疗滤泡性淋巴瘤：SWOG S0016 试验15 年随访结果 CANCER RESEARCH 题目：PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer 翻译：PTEN 氧化促进胰腺癌中PI3K 信号持续激活并诱导巨胞饮作用题目：KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment 翻译：KRASG12R突变型胰腺癌表现为ERK/MAPK 转录活性受限及独特肿瘤微环境题目：Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1 翻译：轴突导向因子 Netrin-1 通过NEO1 促进胰腺肿瘤发生与神经浸润题目：NRF1 Induces ApoEhighCancer-Associated Fibroblasts to Promote Stemness of Renal Cell Carcinoma 翻译：NRF1 诱导高载脂蛋白E 肿瘤相关成纤维细胞促进肾癌细胞干性题目：Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis–Induced Breast Carcinogenesis 翻译：精胺氧化酶是菌群失调诱导乳腺癌发生的关键功能节点题目：Intratumoral Lactobacillus johnsonii Enhances Sensitivity to PD-1 Blockade by Inducing CD8+T-cell Expansion in Hepatocellular Carcinoma 翻译：瘤内约氏乳杆菌通过诱导 CD8+T 细胞扩增增强肝细胞癌对PD-1 抑制剂的敏感性题目：Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy 翻译：TIGIT 碱基编辑重编程NK 细胞CD155 信号以增强肿瘤免疫治疗疗效题目：Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression 翻译：神经促进胃癌与 3 组固有淋巴细胞间相互作用并增强免疫抑制题目：ACSL5 Mediates Adaptation to the Palmitic Acid–Enriched Pulmonary Microenvironment to Enhance Metastatic Breast Cancer Cell Survival and Lung Metastasis 翻译：ACSL5 介导乳腺癌细胞适应富含棕榈酸的肺部微环境，提升转移细胞存活与肺转移能力题目：IDH1 Reprograms Nucleotide Metabolism by Inducing Chromatin Remodeling and DHODHTranscription to Drive Chemoresistance in Nasopharyngeal Carcinoma 翻译：IDH1 通过染色质重塑及DHODH转录重编程核苷酸代谢，驱动鼻咽癌化疗耐药题目：A MERTK-Targeting Antibody–Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells 翻译：靶向 MERTK 的抗体药物偶联物选择性清除M2 型肿瘤相关巨噬细胞及MERTK 阳性肿瘤细胞题目：Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma 翻译：突变型与野生型 RAS 相互作用及计量失衡是KRASG12R 胰腺导管腺癌靶向治疗敏感性的决定因素题目：ETC-501 Is a Brain-Penetrant MNK Inhibitor That Potentiates TMZ-Induced Senescence and Sensitizes Glioblastoma Cells to Senolytic Therapy 翻译：ETC-501 为可透过血脑屏障的MNK 抑制剂，可增强替莫唑胺诱导的衰老并使胶质母细胞瘤对衰老裂解疗法敏感题目：Topology-Based Biomarkers Accurately Predict Breast Cancer Outcome and Survival 翻译：基于拓扑结构的生物标志物可精准预测乳腺癌预后与生存 CLINICAL CANCER RESEARCH 题目：Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results 翻译：ATR 抑制剂卡莫色替布联合低剂量吉西他滨治疗DNA 损伤修复异常实体瘤：临床前与Ⅰb期研究结果题目：A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors 翻译：177Lu -Dotatate 联合卡培他滨对比¹⁷⁷Lu-Dotatate 单药治疗神经内分泌肿瘤的多中心Ⅱ期随机对照试验题目：Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer 翻译：纳武利尤单抗联合或不联合伊匹木单抗新辅助治疗不适用于顺铂的肌层浸润性膀胱癌题目：Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial 翻译：贝考妥革韦多替治疗复发或转移性头颈部鳞状细胞癌：一项多中心Ⅱa期试验题目：18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors 翻译：18F -DOPA-PET 与高级MRI 可改善IDH1/2突变型胶质瘤经IDH 抑制剂治疗后的疗效评估题目：Noninvasive Imaging Assessment of Tertiary Lymphoid Structures and Immunotherapy Response in Gastric Cancer: A Multicenter Study 翻译：胃癌三级淋巴结构的无创影像学评估与免疫治疗疗效：一项多中心研究题目：Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non–Small Cell Lung Cancer 翻译：非小细胞肺癌围手术期化疗联合免疫治疗达病理完全缓解的B 细胞特征解析题目：Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma 翻译：Ⅰ～ⅢB 期黑色素瘤术后ctDNA 动态监测用于疾病随访题目：ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer 翻译：膀胱癌保留器官三联疗法后的 ctDNA 动态变化与复发模式题目：Epigenetic Instability–Based Metrics in Cell-Free DNA for Early Cancer Detection 翻译：基于游离 DNA 表观遗传不稳定性指标的癌症早期检测题目：Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates 翻译：靶向 CD46 的放射免疫抗体药物偶联物协同治疗前列腺癌与多发性骨髓瘤题目：LRRC15-CAR T Cells for the Treatment of Osteosarcoma 翻译：LRRC15 靶向CAR-T 细胞治疗骨肉瘤题目：Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors 翻译：利拉氟替尼耐药复发突变指导FGFR2驱动型肿瘤的治疗序贯策略题目：The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation 翻译：免疫治疗对第二原发恶性肿瘤发生率的影响：抗肿瘤免疫监视激活的替代指标 JOURNAL OF THE NATIONAL CANCER CENTER（本周无更新） JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE（本周无更新） 3.内分泌学与代谢 LANCET DIABETES & ENDOCRINOLOGY 题目：Trends in cause-specific mortality among people with and without diabetes in high-income settings: a multinational, population-based study 翻译：高收入地区糖尿病与非糖尿病人群死因别死亡率趋势：一项多国人群队列研究题目：Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study 翻译：芬兰 1 型糖尿病患者ST 段抬高型与非ST 段抬高型心肌梗死的发病模式及风险特征比较：一项全国队列研究题目：Sex-specific and BMI-specific associations between visceral fat and diabetic kidney disease in patients with diabetes: a large-scale multicentre prospective cohort study 翻译：糖尿病患者内脏脂肪与糖尿病肾病的性别及BMI 特异性关联：一项大规模多中心前瞻性队列研究 DIABETES CARE（本周无更新） 4.心血管病学 CIRCULATION 题目：Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation 翻译：2 型糖尿病患者中GLP-1 受体激动剂与DPP-4 抑制剂或SGLT-2 抑制剂的心衰住院风险比较：一项目标试验模拟研究题目：Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy 翻译：肌小节型与非肌小节型肥厚型心肌病在疾病进程、合并症及死亡率上的差异题目：DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis 翻译：DAPK2 通过调控PKM2 苏氨酸45 位点磷酸化促进紊乱血流诱导的动脉粥样硬化题目：Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device–Mediated Myocardial Recovery in Obese Patients With Heart Failure 翻译：胰岛素抵抗抑制磷酸戊糖途径，并削弱肥胖心衰患者左心室辅助装置介导的心肌功能恢复 EUROPEAN HEART JOURNAL 题目：Nicotine and the cardiovascular system: unmasking a global public health threat 翻译：尼古丁与心血管系统：揭示一项全球性公共卫生威胁题目：Environmental stressors and cardiovascular health: acting locally for global impact in a changing world: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation 翻译：环境应激因素与心血管健康：在变化的世界中立足本地行动以实现全球影响——欧洲心脏病学会、美国心脏病学会、美国心脏协会及世界心脏联合会联合声明题目：C-reactive protein and cardiovascular risk in the general population 翻译：普通人群中 C 反应蛋白与心血管疾病风险题目：Outcomes of cardiovascular screening in men aged 60–64 years: the DANCAVAS II trial 翻译：60–64岁男性心血管筛查结局：DANCAVASⅡ试验题目：Air pollution, meteorological factors, and cardiac remodelling in children: a multi-omics cohort study 翻译：空气污染、气象因素与儿童心脏重构：一项多组学队列研究题目：Peripheral autonomic dysregulation in response to standing: a new form associated with cardiovascular disease, mobility reduction, and cognitive alterations 翻译：站立诱发的外周自主神经功能失调：一种与心血管疾病、活动能力下降及认知改变相关的新类型题目：Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction 翻译：结合临床、代谢组及多基因评分的心血管风险预测 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 题目：Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial 翻译：依托苹果手表提升心房颤动检出率与早期诊断：一项随机对照试验题目：Inappropriate Shocks From Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillators: Individual Participant Data Meta-Analysis of Randomized Trials 翻译：皮下植入式与经静脉植入式心律转复除颤器的不恰当电击比较：随机试验的个体参与者数据荟萃分析题目：Pulsed-Field Ablation to Enhance the Durability of Pulmonary Vein Isolation and Treat Paroxysmal Atrial Fibrillation 翻译：脉冲场消融增强肺静脉隔离持久性并治疗阵发性心房颤动题目：Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy 翻译：脉冲场消融对比标准射频消融治疗典型心房扑动：ADVANTAGE AF 试验亚组研究题目：Underutilized Potential of a Nationwide Community First Responder System 翻译：全国社区第一响应系统未被充分利用的潜力题目：Risk-Guided Atrial Fibrillation Screening With Artificial Intelligence–Enabled Electrocardiogram Models: A VITAL-AF Trial Analysis 翻译：基于人工智能心电图模型的风险导向型房颤筛查：VITAL-AF试验分析 5.胃肠肝病学 LANCET GASTROENTEROLOGY & HEPATOLOGY 题目：Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial 翻译：经肛全直肠系膜切除术对比腹腔镜全直肠系膜切除术治疗中低位直肠癌（COLORⅢ研究）：一项国际多中心Ⅲ期随机对照非劣效性试验的短期结局题目：Indocyanine green fluorescence angiography for anastomotic perfusion assessment in colorectal surgery: a systematic review with meta-analysis, meta-regression, and trial sequential analyses 翻译：吲哚菁绿荧光血管造影在结直肠手术中评估吻合口灌注：一项包含荟萃分析、meta回归及试验序贯分析的系统评价题目：Natural history of chronic hepatitis B in untreated adults without cirrhosis according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis 翻译：基于基线乙肝病毒 DNA 与丙氨酸氨基转移酶水平的无肝硬化未治疗成人慢性乙肝自然病程：系统评价与荟萃分析题目：Efficacy of antiviral therapy in adults with chronic hepatitis B according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis 翻译：基于基线乙肝病毒 DNA 与丙氨酸氨基转移酶水平的成人慢性乙肝抗病毒治疗疗效：系统评价与荟萃分析 JOURNAL OF HEPATOLOGY 题目：MARCO+macrophages drive immunosuppressive remodeling and metastasis in chemotherapy-associated steatohepatitis 翻译：MARCO⁺巨噬细胞在化疗相关性脂肪性肝炎中驱动免疫抑制重塑与转移题目：A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection 翻译：全基因组 siRNA 筛选鉴定出HBV 感染中新型促病毒与抗病毒宿主因子题目：Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B 翻译：Bepirovirsen 结合位点单核苷酸多态性对慢性乙型肝炎治疗应答影响有限题目：Use of intracranial pressure monitoring and risk factors for the development of intracranial hypertension in acute liver failure 翻译：急性肝衰竭中颅内压监测的应用及颅内高压发生的危险因素题目：Targeting ATR to overcome cisplatin resistance in hepatoblastoma 翻译：靶向 ATR 克服肝母细胞瘤顺铂耐药题目：An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC 翻译：基于病因分层的单细胞图谱鉴定 FABP4 为MASLD 相关肝癌预后标志物题目：Molecular profiling and matched targeted treatment in cholangiocarcinoma: Results from the Italian dataset (ANITA) 翻译：胆管癌分子分型与匹配靶向治疗：意大利数据集（ANITA）结果题目：Modeling immune lineage co-development in human pluripotent stem cell-derived liver organoids 翻译：人多能干细胞来源肝类器官中免疫谱系共发育模型构建题目：A single-cell atlas of the woodchuck liver reveals cellular programs conserved in human HBV infection 翻译：土拨鼠肝脏单细胞图谱揭示人类 HBV 感染中保守的细胞程序题目：AF6 knockout-induced upregulation of bile acid production promotes CXCL14-mediated antitumor immunity in HCC 翻译：AF6 敲除诱导胆汁酸生成上调，促进CXCL14 介导的肝癌抗肿瘤免疫 GUT 题目：Circulating extracellular vesicle long RNA profiling combined with machine learning unveils novel diagnostic signature and molecular features in chronic pancreatitis 翻译：循环细胞外囊泡长 RNA 谱结合机器学习揭示慢性胰腺炎新型诊断特征与分子标志物题目：CD16+ γδ T cells mediate antibody-dependent cellular cytotoxicity and associate with viral control in chronic hepatitis B virus infection 翻译：CD16⁺ γδ T 细胞介导抗体依赖的细胞毒性作用，并与慢性乙肝病毒感染的病毒控制相关题目：Targeting PKM2-dependent glycolysis reprogrammes monocytes into Cadm1+ macrophages to promote mucosal repair and attenuate colitis progression 翻译：靶向 PKM2 依赖性糖酵解可将单核细胞重编程为Cadm1⁺巨噬细胞，促进黏膜修复并减缓结肠炎进展题目：Tff2 marks gastric corpus progenitors that give rise to pyloric metaplasia/SPEM following injury 翻译：Tff2标记胃体祖细胞，该类细胞在损伤后可形成幽门化生/ 胃底腺息肉样黏膜化生（SPEM）题目：Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy 翻译：基于基质生物标志物的分型框架：用于识别预后差、免疫治疗获益有限的pMMR/MSS 及dMMR/MSI 结直肠癌 GASTROENTEROLOGY（本周无更新） 6.呼吸病学 LANCET RESPIRATORY MEDICINE（本周无更新） EUROPEAN RESPIRATORY JOURNAL（本周无更新） 7.感染与微生物 LANCET INFECTIOUS DISEASES（本周无更新） LANCET MICROBE（本周无更新） NATURE MICROBIOLOGY 题目：Faecalibacterium prausnitzii enzyme reprograms PD-L1 trafficking and sensitizes colorectal cancer to immunotherapy in mice 翻译：普拉梭菌酶重编程 PD-L1 转运并增强小鼠结直肠癌对免疫治疗的敏感性题目：A bacterial CARD–NLR-like immune system controls the release of gene transfer agents 翻译：细菌类 CARD-NLR 免疫系统调控基因转移因子的释放题目：Structure of Crimean–Congo haemorrhagic fever virus RNA polymerase 翻译：克里米亚 - 刚果出血热病毒RNA 聚合酶结构题目：Impact of intensive control on malaria population genomics under elimination settings in Southeast Asia 翻译：东南亚消除疟疾背景下强化防控对疟原虫群体基因组的影响题目：Acetate utilization strategy in chain-elongating bacteria determines butyrate versus medium-chain carboxylate production 翻译：链延长细菌对乙酸盐的利用策略决定其产生丁酸还是中链羧酸盐题目：Long-term HIV-1 remission achieved through allogeneic haematopoietic stem cell transplant from a CCR5Δ32/Δ32 sibling donor 翻译：采用 CCR5Δ32/Δ32同胞供者异基因造血干细胞移植实现HIV-1 长期缓解 MICROBIOME 题目：Genome-resolved multi-omics provide new insights into microbial nitrogen utilization by the rumen microbiota 翻译：基因组解析的多组学技术为瘤胃微生物群利用氮素提供了新见解题目：Integrated metatranscriptomics identifies Lachnospiraceae as keystone taxa regulating rumen biohydrogenation and milk ω-6/ω-3 polyunsaturated fatty acids ratio in dairy cows 翻译：整合宏转录组学鉴定出毛螺菌科为关键类群，调控奶牛瘤胃生物氢化及乳汁ω-6/ω-3多不饱和脂肪酸比例 JOURNAL OF INFECTION（本周无更新） 8.公共卫生和流行病学 LANCET PUBLIC HEALTH（本周无更新） LANCET GLOBAL HEALTH（本周无更新） 9.内科学 JAMA INTERNAL MEDICINE（本周无更新） ANNALS OF INTERNAL MEDICINE（本周无更新） 10.血液学 LANCET HAEMATOLOGY（本周无更新） 11.牙科与口腔外科 JOURNAL OF CLINICAL PERIODONTOLOGY 题目：Treatment Outcome of Surgical Protocols for Peri-Implantitis: A Retrospective Cohort Study in a Specialised University Centre 翻译：种植体周围炎手术方案的治疗结局：一项来自专业大学诊疗中心的回顾性队列研究题目：Platelet-Rich Fibrin (PRF) Promotes Maxillary Sinus Bone Regeneration: A Randomised Clinical Trial and Proteomic Analysis 翻译：富血小板纤维蛋白（PRF）促进上颌窦骨再生：一项随机临床试验与蛋白质组学分析题目：Free Gingival Grafts With or Without Xenogeneic Collagen Matrix Increase Peri-Implant Keratinised Mucosa in Reconstructed Maxillae: A 1-Year Prospective Cohort Study 翻译：联合或不联合异种胶原基质的游离龈移植术增加重建上颌骨种植周角化黏膜：一项1 年前瞻性队列研究题目：Treatment of Residual Pockets in Stage III and IV Periodontitis Using an Oscillating Chitosan Device With or Without a Chitosan Gel—A Randomised Parallel-Arms Clinical Trial 翻译：搭载或不搭载壳聚糖凝胶的振荡式壳聚糖器械治疗Ⅲ期和Ⅳ期牙周炎残余牙周袋：一项随机平行对照临床试验题目：The Effect of Adjunctive Systemic Antibiotics on the Outcomes of Non-Surgical Periodontal Therapy: A Retrospective Cohort Study 翻译：辅助全身应用抗生素对非手术牙周治疗疗效的影响：一项回顾性队列研究题目：Efficacy of Biologics for Surgical Treatment of Periodontal Suprabony Defects: A Systematic Review and Meta-Analysis of Controlled Clinical Trials 翻译：生物制剂在牙周骨上缺损手术治疗中的疗效：一项对照临床试验的系统评价与荟萃分析题目：Association of Edentulism With Subsequent Biological Age: A Cohort Study 翻译：牙列缺失与后续生物学年龄的关联性：一项队列研究题目：Oral-Rinse-Sourced Microbiota in Oral Health and Diseases in a Representative US Adult Population: Implications for Diagnostics 翻译：美国代表性成年人群口腔健康与疾病状态下漱口液来源的菌群特征：对诊断的启示题目：Untargeted Metabolomic and Lipidomic Profiles of Gingival Crevicular Fluid in the Context of Periodontitis 翻译：牙周炎背景下龈沟液的非靶向代谢组与脂质组谱题目：The Effect of Tobacco Smoking on Tooth Loss: A Systematic Review and Meta-Analysis 翻译：吸烟对牙齿缺失的影响：一项系统评价与荟萃分析题目：Intra-Tissue Bacteriome and Cellular Profiles in Periodontal Granulation Tissue From Osseous Defects and Extraction Sockets 翻译：骨内缺损与拔牙窝牙周肉芽组织内组织菌群及细胞谱特征题目：T2DM-Induced Gut Dysbiosis Exacerbates Periodontitis Through Intestinal Barrier Disruption and Redox Imbalance 翻译：2 型糖尿病诱导的肠道菌群失调通过破坏肠屏障与氧化还原失衡加重牙周炎

2026-04-18

·搜狐新闻

吃海参能抗癌？细胞实验有惊喜，但先别急着下单

海参，自古就是中国餐桌上的名贵滋补品，被称作“海底人参”。但你知道吗？这种软趴趴的海洋生物，也有望成为未来抗癌药物的重要来源！中国有20多种可食用海参，白尾海参是其中一种常见的热带品种。它不仅富含蛋白质，还含有多种具有生物活性的物质，比如三萜皂苷、肽类、糖胺聚糖等。这些成分在传统中医中早已用于抗炎、抗菌、抗凝。近年来，科学家们发现，它们甚至有可能对抗癌细胞！今天就来详细解读这项研究，并告诉您：作为普通消费者，到底该怎么看待“海参抗癌”？文末还有实用小贴士。一、科学家是怎么研究的？研究人员从白尾海参中提取蛋白质，分别在三种癌细胞和三种正常细胞中测试其作用：癌细胞类型正常细胞类型肝癌（HepG2）相应正常肝细胞肺癌（A549）相应正常肺细胞胰腺癌（Panc02）相应正常胰腺细胞主要发现：✅ 海参蛋白能显著抑制癌细胞的生长✅ 能诱导癌细胞凋亡（让癌细胞“自杀”）✅ 对正常细胞几乎没有伤害（选择性好）✅ 还能“卡住”癌细胞的生命周期，让它们无法继续分裂繁殖二、不止杀癌，还防转移？癌症最可怕的就是它的转移能力——癌细胞从原发部位扩散到身体其他器官。这项研究也发现：海参蛋白能抑制癌细胞迁移。也就是说，它可能有“防止癌症转移”的潜力。与常见的化疗药物（如表柔比星）相比，海参蛋白表现出更强的选择性——只攻击癌细胞，不伤害正常组织。这对于未来抗癌药物的研发来说，是一个很大的优势。三、关键问题：吃海参能抗癌吗？先别着急去买海参大补。目前的研究还停留在细胞实验阶段（在培养皿里做的）。想要真正变成药物，还需要走很长的路：阶段状态说明细胞实验 ✅ 已完成在培养皿中看到效果动物实验 ⏳ 待进行需要在活体动物中验证安全性和有效性人体临床试验 ⏳ 待进行需要多期试验确认对癌症患者的真实效果药物上市 ⏳ 遥远即使成功，也需要数年甚至更长时间更重要的一个问题是：海参中的活性蛋白，经过煮、炖、消化后，还能保持活性吗？目前还不清楚。直接吃海参，和实验室里提取的纯化蛋白，完全是两回事。结论：目前不能断言“吃海参能抗癌”。但它提示我们：海洋生物这个“天然药库”，正被科学家们重新认识和挖掘。未来某一天，“海参抗癌蛋白”真的可能成为一种新型抗癌药。四、实用小贴士：科学看待“抗癌食物” 贴士1：区分“细胞实验有效”和“吃了有效” 这是最容易混淆的地方。概念含义举例细胞实验有效在培养皿中，提取物对癌细胞有作用海参蛋白抑制肝癌细胞生长吃了有效通过吃这种食物，能在人体内产生抗癌效果需要临床研究证实绝大多数食物中的活性成分，口服后会被胃酸、消化酶分解，或者在肠道中吸收率极低。细胞实验有效 ≠ 吃了有用。贴士2：不要把海参当“抗癌药”吃经济负担：海参价格不菲，长期大量食用可能给家庭带来不必要的经济压力替代效应：如果把钱和胃口都花在海参上，反而可能挤占了吃其他更重要食物（如蔬菜、水果、全谷物）的空间安全风险：部分海参加工产品可能添加不明成分，或存在重金属污染风险理性建议：如果喜欢吃海参，作为日常营养补充是可以的（前提是经济允许、来源可靠）。但不要指望它替代正规治疗，也不要因为吃了海参就放松其他健康习惯。贴士3：抗癌饮食的真正“黄金法则” 与其追求某一种“神奇食物”，不如关注整体饮食模式：推荐避免/限制每天5份以上蔬菜水果加工肉制品（香肠、培根）全谷物（糙米、燕麦、藜麦）含糖饮料、高糖甜点优质蛋白（鱼、禽、豆制品）高度加工食品健康脂肪（坚果、橄榄油、牛油果）红肉（适量）充足饮水酒精（最好不喝）一句话总结：多样化、植物为主的饮食，比单一“超级食物”重要得多。贴士4：如果想吃海参，注意这几点选择可靠来源：购买正规渠道、有检测报告的产品，避免重金属超标或非法添加适量食用：每周1～2次即可，不需要天天吃正确烹饪：彻底煮熟，避免生食（可能携带细菌或寄生虫）特殊人群慎食：海鲜过敏者痛风急性期患者（海参嘌呤含量中等）肾功能不全者（高蛋白饮食可能增加肾脏负担）正在服用抗凝药物者（海参可能有轻微抗凝作用，需咨询医生）贴士5：如何识别“抗癌食物”的炒作？看到类似新闻时，问自己这几个问题：问题警惕信号是细胞实验还是人体研究？只说“细胞实验发现”，没有人体数据 → 谨慎是提取物还是整食物？研究用的是高浓度提取物，不是直接吃食物 → 谨慎有没有“剂量”信息？如果没说“吃多少才有效”，很可能不现实 → 谨慎有没有夸大宣传？使用“攻克癌症”“神药”“奇迹”等词汇 → 警惕健康的怀疑态度，是保护钱包和身体的最好武器。五、常见问题快问快答问：那海参到底有没有营养？答：有。海参是优质蛋白质来源，低脂肪，含有多种氨基酸和微量元素（如硒、锌）。作为日常食物之一，它是有营养价值的。只是不要神化它的“抗癌”功效。问：化疗期间可以吃海参吗？答：如果患者喜欢吃、经济允许、没有过敏和禁忌症，适量吃是可以的（每周1～2次）。但要先咨询主治医生或营养师，因为：海参可能影响凝血功能（如果正在服用抗凝药）高蛋白饮食对某些患者（如肾功能不全）可能不合适治疗期间消化功能弱，海参不易消化问：有没有其他海洋生物也有抗癌研究？答：有。海洋生物是天然产物的“宝库”，比如：牡蛎：提取物在细胞实验中对某些癌细胞有抑制作用海藻（如褐藻）：含岩藻黄质等成分，研究较多海鞘：已从中开发出抗癌药物（如曲贝替定）但同样，这些都是药物研发的方向，不等于直接吃这些食物能抗癌。问：那我现在应该做什么？答：把注意力放在已经被证实有效的事情上：遵医嘱完成规范治疗和定期复查保持健康体重每天吃够蔬菜水果规律运动不吸烟、限制饮酒管理压力、保证睡眠这些虽然“不新鲜”，但每一件都经过大量研究证实，确确实实能降低复发风险、提高生存率。返回搜狐，查看更多

100 项与曲贝替定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06199	曲贝替定	L01CX01	DB05109

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
平滑肌肉瘤	美国	Janssen Products LP	2015-10-23
软组织肿瘤	日本	Taiho Pharmaceutical Co., Ltd.	2015-09-28
脂肪肉瘤	加拿大	Valeo Pharma, Inc.	2010-08-05
软组织肉瘤	韩国	Verto Korea	2008-04-22
铂敏感性卵巢癌	欧盟	Pharma Mar SA	2007-09-17
铂敏感性卵巢癌	冰岛	Pharma Mar SA	2007-09-17
铂敏感性卵巢癌	列支敦士登	Pharma Mar SA	2007-09-17
铂敏感性卵巢癌	挪威	Pharma Mar SA	2007-09-17
肉瘤	欧盟	Pharma Mar SA	2007-09-17
肉瘤	冰岛	Pharma Mar SA	2007-09-17
肉瘤	列支敦士登	Pharma Mar SA	2007-09-17
肉瘤	挪威	Pharma Mar SA	2007-09-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性软组织肉瘤	临床3期	法国	Pharma Mar SA	2017-11-07
转移性软组织肉瘤	临床3期	德国	Pharma Mar SA	2017-11-07
转移性软组织肉瘤	临床3期	荷兰	Pharma Mar SA	2017-11-07
转移性软组织肉瘤	临床3期	波兰	Pharma Mar SA	2017-11-07
转移性软组织肉瘤	临床3期	西班牙	Pharma Mar SA	2017-11-07
转移性软组织肉瘤	临床3期	英国	Pharma Mar SA	2017-11-07
铂敏感性输卵管癌	临床3期	美国	Pharma Mar SA	2013-10-16
铂敏感性输卵管癌	临床3期	美国	Janssen Research & Development LLC	2013-10-16
铂敏感性输卵管癌	临床3期	中国	Pharma Mar SA	2013-10-16
铂敏感性输卵管癌	临床3期	中国	Janssen Research & Development LLC	2013-10-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO_SRC2026	N/A	平滑肌肉瘤二线	108	Trabectedin	範襯齋淵積膚選鏇製範(鑰範糧艱鬱繭夢餘構醖) = 艱餘蓋餘獵夢壓衊憲餘壓鏇膚蓋艱獵窪構襯鏇 (顧鹽淵獵糧鏇糧構膚選, 5.5 ~ 15.2) 更多	积极	2026-03-09
				gemcitabine-based chemotherapy	範襯齋淵積膚選鏇製範(鑰範糧艱鬱繭夢餘構醖) = 餘積淵遞廠選淵範憲鬱壓鏇膚蓋艱獵窪構襯鏇 (顧鹽淵獵糧鏇糧構膚選, 3.8 ~ 6.4) 更多
ESMO_ASIA2025	N/A	肉瘤	9	Trabectedin	範餘範壓夢糧獵製壓獵(艱網糧廠夢繭鹽願顧壓) = In one case of FUS::DDIT3-positive myxoid liposarcoma, fourth-line trabectedin therapy was initiated. A partial response was achieved after 12 months of treatment, and disease control has been maintained for 15 months, with therapy still ongoing. 網觸鏇壓築築壓壓鑰糧 (鏇憲製製蓋淵鹹積遞獵 )	积极	2025-12-05
				Trabectedin (Fusion/Rearrangement-Positive)
NCT03085225 (TRAMUNE, CTgov)	临床1期	局部晚期软组织肉瘤 \| 卵巢癌 \| 软组织肉瘤	40	Trabectedin (Dose Escalation (Trabectedin Dose Level 1,0 mg/m²))	淵廠壓選齋鏇艱願顧窪 = 鑰鏇鏇築願壓構蓋憲構構構壓繭餘鏇廠淵蓋鬱 (顧窪醖壓衊夢選鹹築齋, 選齋憲獵淵夢夢願窪遞 ~ 範衊餘鹽鹽繭餘鑰願顧) 更多	-	2025-09-04
				Trabectedin (Dose Escalation (Trabectedin Dose Level 1,2 mg/m²))	淵廠壓選齋鏇艱願顧窪 = 壓鏇遞築糧鹹構構膚鏇構構壓繭餘鏇廠淵蓋鬱 (顧窪醖壓衊夢選鹹築齋, 衊繭願廠構製鹽蓋願鏇 ~ 窪廠鑰獵膚繭鹽願鏇蓋) 更多
NCT02234050 (EORTC-BTG-1320 \| EORTC-1320-BTG, CTgov)	临床2期	-	90	Local standard of care (Local Standard of Care)	願鬱蓋鑰願齋鏇壓衊鑰(願顧鏇網範鑰襯齋鑰鑰) = 餘齋鏇齋選鏇窪壓衊憲繭築膚繭顧遞網窪夢壓 (糧構鏇選鑰鬱襯網選範, 窪鏇蓋鹹蓋觸餘築築蓋 ~ 鑰蓋糧蓋襯築艱襯製鬱) 更多	-	2025-07-10
				Trabectedin (Trabectedin)	願鬱蓋鑰願齋鏇壓衊鑰(願顧鏇網範鑰襯齋鑰鑰) = 壓簾鹽艱範淵遞醖選觸繭築膚繭顧遞網窪夢壓 (糧構鏇選鑰鬱襯網選範, 鑰夢築觸襯艱範蓋網遞 ~ 窪蓋鏇構憲廠製窪夢顧) 更多
T-DIS (ASCO2025)	N/A	粘液样脂肪肉瘤维持	79	Stop-and-go strategy with Trabectedin	糧餘醖製蓋範願衊構餘(衊衊艱鹽憲襯壓齋遞壓) = 艱願鏇衊糧膚淵餘醖鬱鏇築淵築鹽願膚糧齋膚 (糧積衊構獵繭範齋鹹觸, 37.1 ~ NA) 更多	积极	2025-05-30
				Trabectedin maintenance	糧餘醖製蓋範願衊構餘(衊衊艱鹽憲襯壓齋遞壓) = 衊獵簾選簾簾餘糧顧選鏇築淵築鹽願膚糧齋膚 (糧積衊構獵繭範齋鹹觸, 6.6 ~ 17.7) 更多
ESMO_SRC2025	N/A	软组织肉瘤 Cytochrome P450 (CYP 3A4)	51	Trabectedin	夢積糧齋壓憲餘窪襯膚(網窪艱糧顧艱積鬱襯選) = 衊蓋淵獵願遞蓋繭醖築鬱鹽範選觸鹹鹹糧鏇構 (繭壓簾鑰襯淵夢壓蓋壓 )	积极	2025-03-21
ESMO_SRC2025	N/A	朗格汉斯细胞肉瘤	332	Trabectedin RDI<80%	製艱膚膚範範選範膚鬱(窪顧夢糧窪築顧膚窪餘) = 鹹艱製壓齋遞窪鏇壓窪繭壓艱鑰廠膚積膚醖範 (艱膚艱鬱獵製齋餘壓廠 ) 更多	不佳	2025-03-21
				Trabectedin RDI≥80%	製艱膚膚範範選範膚鬱(窪顧夢糧窪築顧膚窪餘) = 夢顧觸蓋鹹衊獵壓構繭繭壓艱鑰廠膚積膚醖範 (艱膚艱鬱獵製齋餘壓廠 ) 更多
NCT03164980 (COMPASS, CTgov)	临床4期	铂敏感性原发性腹膜癌 \| 复发性卵巢癌 \| 铂敏感性卵巢癌 ... 更多	89	Trabectidin (Yondelis) (Arm A)	繭築願壓壓醖鹹廠鹽選(觸願範築壓築遞鑰築餘) = 醖鏇糧衊範網獵製襯繭鏇蓋膚膚憲鏇襯範鏇鏇 (壓觸構壓鬱壓憲鬱蓋糧, 15.6) 更多	-	2025-03-20
				Trabectidin (Yondelis) (Arm B)	繭築願壓壓醖鹹廠鹽選(觸願範築壓築遞鑰築餘) = 顧艱簾蓋糧選簾淵獵選鏇蓋膚膚憲鏇襯範鏇鏇 (壓觸構壓鬱壓憲鬱蓋糧, 14.7) 更多
NCT03127215 (AIO-STS \| TF-0117 \| ass, ESMO2024) 人工标引	临床2期	实体瘤 DNA repair deficiencies	117	Trabectedin olaparib (TrO)TrO)	遞淵顧廠鑰夢願築憲艱(鬱簾積廠憲鏇憲構鹽憲) = 鏇壓鑰襯窪鹹顧願鹽憲築簾鏇鏇鹽顧構製範糧 (膚憲範鑰築壓遞願齋範 ) 更多	不佳	2024-09-15
				Physician’s choice (PC)	遞淵顧廠鑰夢願築憲艱(鬱簾積廠憲鏇憲構鹽憲) = 築網壓廠選網鹹糧製糧築簾鏇鏇鹽顧構製範糧 (膚憲範鑰築壓遞願齋範 )
NCT03138161 (SAINT, ESMO2024) 人工标引	临床2期	软组织肉瘤一线	97	TrabectedinIpilimumabnivolumab	蓋範製蓋糧製選鹹簾糧(構齋範鹽鹽鑰衊壓壓艱) = 繭艱膚選糧餘範製積齋積膚積積醖糧鬱簾積構 (艱築簾鹽壓襯醖鹹鹽構, 5.247 ~ 9.353) 更多	积极	2024-09-14